Shots:
- BI has reported P-III (SYNCHRONIZE-1) trial assessing survodutide (BI 456906; 3.6 or 6mg, QW) vs PBO in 725 adults living with obesity or overweight, without type 2 diabetes
- Trial met co-1EP, with ~85.1% achieving ≥5% weight loss vs 38.8%, & 16.6% sustained mean loss vs 3.2% after 76wks. (efficacy estimand), mainly driven by fat loss, with minimal lean mass loss, & also showed significant waist circumference reduction (2EP)
- Full Phase III data will be presented at the ADA’26, with additional readouts expected in 2026, while survodutide is also being evaluated in global P-III (LIVERAGE & LIVERAGE-Cirrhosis) trials in MASH & fibrosis stages 2/3 and compensated MASH cirrhosis (fibrosis stage 4)
Ref: Globenewswire | Image: BI | Press Release
Related News: Boehringer Ingelheim Secures US FDA’s EUA for Ivomec (ivermectin) to Prevent New World Screwworm Infestations in Cattle
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
